ASO VISUAL ABSTRACT


ASO Visual Abstract: Outcomes of Advanced MTC in the Era of Targeted Therapy

Nicholas L. Kesby^{1,2}, Alexander J. Papachristos, MBBS (Hons)¹, Matti Gild, BSc, MBBS (Hons), PhD^{3,4,5}, Ahmad Aniss, BSc, MSc, PhD¹, Mark S. Sywak, MBBS, MMed (Clin Epi)^{1,3}, Roderick Clifton-Bligh, BSc, MBBS (Hons), PhD^{3,4,5}, Stan B. Sidhu, MBBS (Hons), PhD^{1,3,4}, and Anthony R. Glover, MBBS, PhD^{1,2,3}

¹Royal North Shore Hospital, Endocrine Surgical Unit, Northern Sydney Local Health District, St. Leonards, NSW, Australia; ²Garvan Institute of Medical Research, Endocrine Cancer Program, The Kinghorn Cancer Centre and St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; ³Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; ⁴Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia; ⁵Department of Endocrinology, Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, Sydney, Australia

Our retrospective cohort study (https://doi.org/10.1245/s10434-021-10980-5) describes outcomes of total thyroidectomy for medullary thyroid cancer, comparing those

presenting with early versus advanced disease, and evaluates the impact of tyrosine kinase inhibitor use on overall survival.



© Society of Surgical Oncology 2021

Published Online: 8 November 2021

A. R. Glover, MBBS, PhD

e-mail: anthony.glover@sydney.edu.au; antglover@gmail.com

DISCLOSURES Roderick Clifton-Bligh: advisory board and speaker bureau for Amgen and Eisai.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.